Dr. Aiming Pang: The “Tianjin Model” of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

Dr. Aiming Pang: The “Tianjin Model” of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

Autologous hematopoietic stem cell transplantation (ASCT) is a treatment option for adult acute leukemia in remission. Compared to allogeneic hematopoietic stem cell transplantation (allo-HSCT), ASCT has advantages such as no donor restrictions, absence of graft-versus-host disease (GVHD), and a lower transplant-related mortality rate. At the recent "4th Shanghai Symposium on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation," Dr. Aimang Pang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, delivered an insightful presentation on the "Tianjin Model" for ASCT in treating acute leukemia. The highlights of the presentation are summarized here for our readers.
Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

The 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, recently took place in Tianjin, drawing hundreds of leading experts and scholars in the field of hematology from around the world. During the conference, Hematology Frontier invited Dr. He Huang from The First Affiliated Hospital, Zhejiang University School of Medicine and Dr. Didier Blaise from the Hematology Institute of Aix-Marseille University in France to engage in a dialogue on the challenges and opportunities in new cellular therapies for hematologic malignancies. Here are the key insights from their conversation.
Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients

Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients

Due to factors such as early screening, drug accessibility, and genetic differences, prostate cancer characteristics in China differ from those in Western countries. In recent years, with China's aging population, the incidence and mortality of prostate cancer have risen significantly, increasing the disease burden. At the recent CSCO Annual Meeting, Urology Frontier invited Dr. Yao Zhu from Fudan University Shanghai Cancer Center to share insights on the characteristics of prostate cancer in China, the latest research progress at Fudan, and the value of clinical research by physicians.
CSCO 2024丨Dr. Ou Bai: The Development and Growth of the Lymphoma Specialty at The First Bethune Hospital of Jilin University

CSCO 2024丨Dr. Ou Bai: The Development and Growth of the Lymphoma Specialty at The First Bethune Hospital of Jilin University

From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. The conference, themed "Patient-Centered, Sharing the Future," brings together the latest research advancements and developments in the field, both domestically and internationally. For more than 20 years, CSCO has been at the forefront of clinical oncology in China, with experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series, inviting Chinese scholars to revisit past stories. In this issue, we invited Dr. Ou Bai, a member of the CSCO United Committee for Lymphoma Intervention (UCLI) and a key figure in the development of the lymphoma specialty at The First Bethune Hospital of Jilin University, to share the story of growing together with CSCO.
CSCO 2024丨Dr. Sanjun Cai: Perioperative “Three-Pronged Strategy” Brings More Options for Colorectal Cancer Treatment

CSCO 2024丨Dr. Sanjun Cai: Perioperative “Three-Pronged Strategy” Brings More Options for Colorectal Cancer Treatment

From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and CSCO Academic Annual Meeting was successfully held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference gathered significant research progress and developments from both domestic and international fields. Dr. Sanjun Cai from Fudan University Shanghai Cancer Center chaired the special session on perioperative treatment for colorectal cancer at this year’s conference. During the event, Oncology Frontier conducted an interview with Professor Cai to discuss recent advances and challenges in perioperative colorectal cancer treatment. Below is a summary of the interview to provide insight for the readers.
CSCO 2024 | Dr. Gong Chen Provides an In-Depth Analysis of the Changing Treatment Paradigm for Locally Advanced Colorectal Cancer

CSCO 2024 | Dr. Gong Chen Provides an In-Depth Analysis of the Changing Treatment Paradigm for Locally Advanced Colorectal Cancer

From September 25 to 29, 2024, the much-anticipated 27th Annual Chinese Society of Clinical Oncology (CSCO) conference was held successfully in Xiamen. This prominent event gathered top experts from China's oncology community, focusing on standardized pathways and cutting-edge advancements in the diagnosis and treatment of malignant tumors.During the conference, Dr. Gong Chen from the Sun Yat-sen University Cancer Center delivered a well-received presentation titled "The Evolving Treatment Paradigm for Locally Advanced Colorectal Cancer." In this golden moment of academic exchange, Oncology Frontier conducted a deep interview with Professor Chen. The discussion centered around the latest advancements in the treatment of locally advanced colorectal cancer and his long-standing academic connection with CSCO, offering an insightful blend of professional wisdom and personal emotion.
CSCO 2024 | Dr. Baorui Liu: “Rapid Advancements in Gastric Cancer Treatment, A Bright Future for Young Scholars”

CSCO 2024 | Dr. Baorui Liu: “Rapid Advancements in Gastric Cancer Treatment, A Bright Future for Young Scholars”

The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting was held in Xiamen from September 25 to 29, 2024. This year’s theme, “Patient-Centered, Future-Sharing,” brought together major research advancements and developments from around the world. A dedicated gastric cancer session was organized, gathering top experts in the field to explore the latest progress, technologies, and concepts in gastric cancer treatment. We invited Dr. Baorui Liu, Chair of the gastric cancer session and Director of the Oncology Center at Nanjing Drum Tower Hospital,The Affiliated Hospita of Nanjing University Medical School to share key highlights and discussions from the session.
ETER100 Study Showcased at ESMO Late-Breaking Abstract Session: Dr. Xinan Sheng Shares New Advances in Targeted and Immunotherapy

ETER100 Study Showcased at ESMO Late-Breaking Abstract Session: Dr. Xinan Sheng Shares New Advances in Targeted and Immunotherapy

Renal cell carcinoma (RCC) is one of the most common malignancies of the urinary system. In recent years, the exploration of combined immunotherapy strategies in RCC has transformed the treatment landscape, making immuno-targeted therapy the global first-line standard for advanced renal cancer. The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain, from September 13 to 17. During the Urothelial Cancer (non-prostate) Short Oral Presentation session on September 15, Dr. Xinan Sheng from Peking University Cancer Hospital delivered a presentation titled "Anlotinib in combination with the anti-PD-L1 antibody Benmelstobart (TQB2450) versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) - A randomized, open-label, phase III study (ETER100)." This was the only late-breaking abstract (LBA) study from China selected in the field of uro-oncology at this year's ESMO conference. Urology Frontier invited Professor Sheng to elaborate on the current state of advanced renal cancer treatment in China, the survival benefits and safety of combined immunotherapy in advanced RCC, and other key topics.